Vimta Labs Ltd-$ — Q4 FY26 earnings call
Summary generated by AI from the official transcript Vimta Labs Ltd-$ filed with BSE on 12 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Vimta Labs reported Q4 FY'26 total income of INR1,120 million, up 16.6% year-on-year, with EBITDA of INR421 million and PAT of INR211 million. For the full year FY'26, total income rose 19.5% to INR4,163 million with EBITDA margin at 35.8% and PAT margin at 18.6%. Management discussed the entry into biologics contract research services, export revenue of around 38% in Q4, and commented on the impact of geopolitical tensions and tariffs on input costs and supply chains.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Total income: INR1,120 million (Q4 FY'26)
p. 4
“Total income for Q4 FY '26 stood at INR1,120 million as compared to INR961 million in Q4 FY '25, up by almost 16.6% year-on-”
Siva Rama Krishna, page 4 of the filed PDF · View the filing
EBITDA: INR421 million (Q4 FY'26)
p. 5
“EBITDA stood at INR421 million in Q4 FY '26 as compared to INR347 million in Q4 FY '25, up by almost 21.5% year-on-year.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
EBITDA margin: 37.6% (Q4 FY'26)
p. 5
“EBITDA margins for the quarter stood at 37.6%.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Profit after tax: INR211 million (Q4 FY'26)
p. 5
“Profit after tax in Q4 FY '26 stood at INR211 million as compared to INR183 million in FY '25, a growth of 15.2% year-on-year.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
PAT margin: 18.9% (Q4 FY'26)
p. 5
“PAT margins for the quarter stood at 18.9%.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Basic EPS: INR4.7 (Q4 FY'26)
p. 5
“Basic EPS was at INR4.7.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Total income: INR4,163 million (FY'26)
p. 5
“Coming to yearly performance, total income for FY '26 was at INR4,163 million as compared to INR3,482 million in FY '25, up by 19.5% year-on-year.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
EBITDA: INR1,489 million (FY'26)
p. 5
“EBITDA for FY '26 was INR1,489 million as compared to INR1,262 million in FY '25, a growth of 18% year-on-year.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
EBITDA margin: 35.8% (FY'26)
p. 5
“EBITDA margin for the year is at 35.8%.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
PAT margin: 18.6% (FY'26)
p. 5
“PAT margin was at 18.6%.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Basic EPS: INR17.4 per share (FY'26)
p. 5
“Basic EPS for the full year was at INR17.4 per share.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Cash and cash equivalents: close to INR650 million (FY'26 year-end)
p. 5
“we continue to have a net debt-free balance sheet with the cash and cash equivalents including bank balances close to INR650 million.”
Siva Rama Krishna, page 5 of the filed PDF · View the filing
Export revenue: around 38% (Q4 FY'26)
p. 11
“In Q4 it has been around 38%.”
Harita Vasireddi, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA margin — stable and competitive range · medium term
stated as an aspiration by Harita Vasireddi
p. 4
“our focus remains on sustaining margins in a stable and competitive range over the medium term.”
Harita Vasireddi, page 4 of the filed PDF · View the filing
Revenue — INR120 crores, INR130 crores every quarter
stated as an aspiration by Harita Vasireddi
p. 10
“Yes, that's the intent to keep moving at this momentum.”
Harita Vasireddi, page 10 of the filed PDF · View the filing
Revenue CAGR — 20% to 25% CAGR · next three to four years
stated as an aspiration by Harita Vasireddi
p. 8
“It's a stretch number, but definitely doable. And that's what we target each year.”
Harita Vasireddi, page 8 of the filed PDF · View the filing
EBITDA margin — correction of 1%, 2%
stated conditionally by Harita Vasireddi
p. 8
“So you can expect a correction of 1%, 2% depending on how things are panning out right now because if the input cost goes up, there could be some impact for us there.”
Harita Vasireddi, page 8 of the filed PDF · View the filing
Revenue — INR500 crores annualized · FY27
stated as an aspiration by Harita Vasireddi
p. 13
“But going forward, we are hopeful, very, very hopeful. But there are uncertainties in the environment now, as you all know.”
Harita Vasireddi, page 13 of the filed PDF · View the filing
Biologics contract research revenue contribution — FY27
stated as an aspiration by Harita Vasireddi
p. 5
“Maybe not in its maiden year, too soon to comment on that. But this year, what we hope to do is build traction in the market, on-board at least a few good clients and deliver well.”
Harita Vasireddi, page 5 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management does not break out margins by service line and said pharma and food testing will continue to drive growth.
Answered by Harita Vasireddi
Asked by Shreya Chatterjee: Can you give margin profile by vertical and the highest growth driver going forward, plus a biologics update?
p. 5
“We don't differentiate the margins between our service lines. It's all treated as one service, so that information is not available.”
Harita Vasireddi, page 5 of the filed PDF · View the filing
Management said there was some direct impact on input costs and supply chain lead times due to the war, with the future impact uncertain.
Answered by Harita Vasireddi
Asked by Yogesh Patil: What is the impact of the current global environment, including US trade issues and Iran-US war, on revenue booking?
p. 7
“Impact of war is there on us. The cost of some input materials, consumables has gone up slightly. There is a slightly longer lead time for us in the supply chain.”
Harita Vasireddi, page 7 of the filed PDF · View the filing
Management said they have inquiries from Europe, India, and the US and are finalizing the product and modality.
Answered by Neerukonda Sreenivas
Asked by Vishal Manchanda: Have you signed clients yet on the biosimilar side?
p. 10
“We have good inquiries and we will be closing them soon. We have good traction from Europe, from India, a couple of them from US as well.”
Neerukonda Sreenivas, page 10 of the filed PDF · View the filing
Management said there was an impact in the last fortnight of March affecting exporters and import testing.
Answered by Harita Vasireddi
Asked by Rohan Shah: Has the war impacted the food testing business this quarter?
p. 10
“There was an impact especially the last fortnight of March because we serve exporters and we also support import testing at the NFL in Navi Mumbai.”
Harita Vasireddi, page 10 of the filed PDF · View the filing
Management said last year was not exciting due to leadership challenges that have now been fixed, with retained customers and strong word of mouth.
Answered by Harita Vasireddi
Asked by Rohan Shah: How are electronics and electrical testing scaling and what is the medium-term potential?
p. 12
“Last year for us has not been very exciting in this segment. We were hoping that we would pick up some more momentum here, but we had leadership challenges which are fixed now.”
Harita Vasireddi, page 12 of the filed PDF · View the filing
Management said the original goal was to hit INR500 crores by last year but external headwinds and divestment effects delayed this, and they remain hopeful but note uncertainties.
Answered by Harita Vasireddi
Asked by Amita Modi: Where does the company stand on its INR500 crores annualized revenue plan and can it be achieved in FY27?
p. 13
“Our goal was to hit INR500 crores by last year, but because of divestment of diagnostics, we said we will try and get to those run rates by Q4.”
Harita Vasireddi, page 13 of the filed PDF · View the filing
Risks flagged
Geopolitical war impact on input costs and supply chain lead times
p. 7
“The cost of some input materials, consumables has gone up slightly. There is a slightly longer lead time for us in the supply chain.”
Harita Vasireddi, page 7 of the filed PDF · View the filing
US tariffs strained the pharmaceutical industry last year
p. 7
“I think the pharmaceutical industry was under strain because of the tariffs imposed by US.”
Harita Vasireddi, page 7 of the filed PDF · View the filing
Talent availability and attrition remain industry-wide challenges
p. 4
“While talent availability and attrition remain industry-wide challenges, we have successfully retained critical scientific and leadership talent”
Harita Vasireddi, page 4 of the filed PDF · View the filing
Leadership challenges in electronics and electrical testing segment
p. 12
“we had leadership challenges which are fixed now.”
Harita Vasireddi, page 12 of the filed PDF · View the filing
Impact on food testing exports and imports from war in last fortnight of March
p. 10
“There was an impact especially the last fortnight of March because we serve exporters and we also support import testing at the NFL in Navi Mumbai.”
Harita Vasireddi, page 10 of the filed PDF · View the filing
Rising manpower costs pressuring margins
p. 8
“manpower is something that continuously keeps on increasing, but we try to offset with the top line growth.”
Harita Vasireddi, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.